Table 1 Patient demographics and clinical characteristics.
From: Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus
Patient number | Sex | Diagnosis | Site involvement | Reason for inclusión | ANA/dsDNAα antibodies | Anti-Ro/SSA/La/SSB antibodies | CLASI A/D | Previous received treatment |
|---|---|---|---|---|---|---|---|---|
1 | F | DLE (L) | V-neck, arm | T lack of efficacy, PN | 1/640 (123) | +/- | 6/2 | TCS, OCS, HCQ, T |
2 | F | Lupus Profundus | Arm, back | T lack of efficacy | 1/160 (-) | -/- | 7/1 | TCS, OCS, HCQ, T |
3 | F | DLE (L) | Arm | T lack of efficacy | 1/640 (-) | -/- | 3/1 | TCS, OCS, HCQ, T |
4 | F | ACLE | Face, v-neck | T side effects | 1/640 (54) | -/- | 6/0 | TCS, OCS, HCQ, T, AZA, |
5 | F | Lupus Profundus | Scalp, face, arms | T side effects | 1/640 (144) | -/- | 19/6 | TCS, OCS, HCQ, MMF, T |
6 | F | SCLE | Face, v-neck, back | > 18% body surface | 1/640 (-) | +/- | 19/0 | TCS, OCS, MMF |
7 | F | SCLE | Face, v-neck, hands, arms | T side effects, PN, > 18% body surface | 1/640 (83) | -/- | 20/1 | TCS, OCS, HCQ, AZA, T |
8 | F | DLE (L) | Face, scalp, ear lobe | T side effects | 1/40 (-) | -/- | 9/0 | TCS, OCS, HCQ, T |
9 | F | DLE (G) | Face, ear lobe, arms, neck | > 18% body surface, T side effects | 1/320 (37) | -/- | 13/2 | TCS, OCS, HCQ, MMF, T |
10 | F | LET | Face | T side effects, PN | 1/640 (-) | -/- | 6/0 | TCS, HCQ, T |
11 | F | DLE (G) | Face, scalp, back | T side effects, > 18% body surface | 1/40 (-) | +/- | 15/9 | TCS, OCS, HCQ, T |
12 | F | DLE (G) | Face, v-neck, back, scalp | T side effects, PN | 1/40 (-) | +/- | 17/8 | TCS, OCS, HCQ, T |
13 | F | DLE (L) | Face | T lack of efficacy | 1/160 (-) | -/- | 3/0 | TCS, HCQ, T |
14 | F | DLE (G) | Face, v-neck | T side effects | 1/640 (-) | -/- | 11/2 | TCS, OCS, HCQ, MMF, T |
15 | F | DLE (L) | Face, scalp | T side effects | 1/40 (-) | -/- | 10/3 | TCS, OCS, HCQ, T |